Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
ID: 358818Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358818

Additional Information

https://grants.nih.gov/grants/guide/notice-files/NOT-TR-25-008.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN), aimed at advancing research for over 10,000 rare diseases in the U.S. This funding opportunity encourages collaborative, multi-site, patient-centric clinical trials to enhance the diagnosis, management, and treatment of rare diseases, with a focus on innovative approaches and the involvement of patient advocacy groups. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, for-profit organizations, and various levels of government, with funding amounts ranging from $0 to $1 million. Interested parties should note that the application deadline is October 16, 2025, and can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov for further information.

    Point(s) of Contact
    urvtiin@mail.nih.gov
    Files
    Title
    Posted
    NOT-TR-25-008.html
    The National Center for Advancing Translational Sciences (NCATS) plans to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) within the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to advance research on rare diseases by encouraging collaborative, multi-site, patient-centered clinical trials. The upcoming NOFO, released on May 5, 2025, invites applications focused on at least three distinct rare diseases and requires each consortium to propose two to four clinical research projects, including one longitudinal study. Key areas of focus include early-stage clinical trials, biomarker studies, and the development of patient-reported outcomes. Applications must emphasize collaborative, multidisciplinary efforts that involve patients, clinicians, researchers, and other stakeholders. The document outlines eligibility criteria for various organizations and emphasizes that awarded projects will support research activities significantly involving NIH program staff. The funding framework will depend on available resources, with specific areas of interest determined at the time of the NOFO publication. This effort aims to foster innovative approaches to enhance the development of effective treatments and interventions for individuals affected by rare diseases.
    PAR-25-438_.html
    The Department of Health and Human Services, through the National Institutes of Health, announces a funding opportunity aimed at advancing research for rare diseases through the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative seeks applications for new and renewed funding to enhance diagnosis, management, and treatment of rare diseases, focusing on patient-centric, multi-site, and collaborative research. The funding aims to address significant public health challenges associated with over 10,000 rare diseases in the U.S., which currently lack effective treatments. Key support structures include a Data Management and Coordinating Center (DMCC) to facilitate data sharing, standardization, and support, along with significant involvement from patient advocacy groups. Each RDCRC must engage in at least one longitudinal study, emphasizing the importance of understanding disease progression to support effective clinical trials. The program encourages innovative approaches and collaboration across various stakeholders, aligning with similar efforts from participating NIH institutes. The goal is to foster research that moves towards clinical trial readiness, leveraging existing knowledge and promoting the rapid development of treatments for rare diseases.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish the re-issuance of the Notice of Funding Opportunity (NOFO) Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) under the Rare Diseases Clinical Research Network (RDCRN), aimed at enhancing research in the diagnosis, management, and treatment of rare diseases. Each RDCRC is required to focus on at least three rare diseases and propose two to four clinical research projects, including one longitudinal study, emphasizing a collaborative, multi-site approach to address significant clinical trial readiness gaps. This initiative reflects the government's commitment to advancing public health through innovative methodologies and stakeholder engagement in the rare disease domain, with applications expected to be due in June and fall of 2025. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for preclinical proof of concept studies targeting rare diseases under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established preclinical models for therapeutic agents, including small molecules and biologics, with the goal of advancing projects toward Investigational New Drug (IND) applications. The funding is particularly significant as it addresses the unmet medical needs of approximately 30 million individuals in the U.S. affected by rare diseases, enhancing the likelihood of progressing novel therapies to clinical trials. The total funding available is up to $1,200,000 for FY26, with a maximum budget of $275,000 per two-year project. Interested applicants must submit their letters of intent by May 1, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html.
    Forecast for Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the R21 grant aimed at enhancing clinical trial readiness for rare diseases, disorders, and syndromes. This initiative seeks to support research projects that address critical needs in the field, such as the development of biomarkers and clinical outcome measures, which are essential for facilitating the transition of therapeutics and diagnostics into clinical trials. The opportunity is particularly significant as it aims to improve the success rates of clinical trials for rare diseases, which often face unique challenges. Interested small businesses are encouraged to begin forming collaborations and developing proposals, with the estimated synopsis posting date set for November 14, 2025, and applications expected to be accepted until February 16, 2026. For further inquiries, potential applicants can contact Dr. Alice Chen Grady at alice.chen2@nih.gov or by phone at 301-827-2015.
    Infectious Diseases Clinical Trials Network (IDCTN)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Infectious Diseases Clinical Trials Network (IDCTN)" aimed at advancing public health through the rapid implementation of clinical trials for infectious diseases. This initiative seeks to establish a network comprising Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC) to evaluate therapeutics, vaccines, diagnostics, and devices, addressing urgent public health needs that standard grant timelines cannot meet. With an estimated total program funding of $29 million, this opportunity is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, and community-based organizations. Interested parties can reach out to Dr. Marina S. Lee at 240-627-3304 or via email at dmidclinicaltrials@niaid.nih.gov for further information, with key deadlines including an estimated synopsis close date of June 11, 2026, and an anticipated award date of March 1, 2027.
    NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional) aimed at advancing the diagnosis, prevention, treatment, and amelioration of human sensory and communication disorders. This funding opportunity supports integrated, multidisciplinary research programs that include 3-4 synergistic research projects and an administrative core, with the possibility of 1-2 optional scientific cores, all centered around a unifying clinical theme. The maximum project period is five years, with budgets capped at $1,500,000 in direct costs per year for new applications. Eligible applicants include various organizations, excluding foreign entities, and are encouraged to consult with NIDCD staff prior to submission to ensure responsiveness. The application deadline is June 2, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.